Click to view timeline
Timeline
Former Teams
Publications
Download-
2024A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model., J Virol 2024 Apr; (): e0169323.
-
2022Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study., EBioMedicine 2022 Jan; 75(): 103810.